MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
|Videos|April 30, 2021
The Evolving Diagnostic Criteria for Multiple Sclerosis
Join Ahmed Obeidat, MD, PhD; Hesham Abboud, MD, PhD; and Rana K. Zabad, MD, FAAN, for perspectives on how the diagnostic criteria for multiple sclerosis have evolved over time.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Hesham Abboud, MD, PhD
Assistant Professor of Neurology, Case Western Reserve University School of Medicine; Director, Multiple Sclerosis and Neuroimmunology Program, Staff Neurologist, Parkinson’s and Movement Disorders Center, University Hospitals, Cleveland Medical Center - Rana K. Zabad, MD, FAAN
Professor, Department of Neurological Sciences, Chief, Multiple Sclerosis/Neuroimmunology Section, Program Director, Multiple Sclerosis Fellowship, University of Nebraska Medical Center
Key Learning Objectives
- Virtual patient visits during COVID-19 when diagnosing MS
- Review of the revised 2017 McDonald criteria
- Determining MS mimickers
- The future of diagnosing MS
Resources
Advertisement
Related to this article
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
Here's some of what is coming soon to NeurologyLive® this week.
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows
4
Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype
5